Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.46 |
| ▸ | CALML3 | P27482 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637825 | 1.00 | MAOA (0.46) | MAOACALML3MAOBCYP3A4CYP2C19 | |
| SCHEMBL6634716 | 0.90 | MAOA (0.60) | MAOACALML3MAOBF10 | |
| SCHEMBL6634714 | 0.85 | MAOA (0.40) | MAOACALML3MAOBCYP3A4CYP2C19 | |
| SCHEMBL6635519 | 0.85 | CALML3 (0.48) | MAOACALML3MAOBCYP3A4CYP2C19 | |
| SCHEMBL6706437 | 0.85 | CALML3 (0.48) | MAOACALML3MAOBCYP3A4CYP2C19 | |
| SCHEMBL6638909 | 0.84 | CALML3 (0.48) | MAOACALML3CYP3A4F10 | |
| SCHEMBL6638913 | 0.84 | CALML3 (0.48) | MAOACALML3CYP3A4F10 | |
| SCHEMBL6634648 | 0.84 | CALML3 (0.46) | MAOACALML3CYP3A4CYP2C19 | |
| SCHEMBL6634642 | 0.84 | CALML3 (0.46) | MAOACALML3CYP3A4CYP2C19 | |
| SCHEMBL6707507 | 0.84 | CALML3 (0.46) | MAOACALML3MAOBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828317-B2 | Bactericides; gramnegative, grampositive bacteria | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| EP-1472247-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040014746-A1 | Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections | LEUHR GARY W (US) | 2004-01-22 | — | — | US | disclosed |
| WO-2003066631-A1 | ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014746-A1 | Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections | TBCD, THPO, NISCH | MAOA 2120/4885CALML3 4231/4885MAOB 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.